Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Poseida Therapeutics Q3 EPS $0.21 Beats $(0.41) Estimate, Sales $71.75M Beat $16.27M Estimate

Author: Benzinga Newsdesk | November 07, 2024 05:27pm
Poseida Therapeutics (NASDAQ:PSTX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.41) by 151.22 percent. This is a 160 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $71.75 million which beat the analyst consensus estimate of $16.27 million by 340.98 percent. This is a 667.19 percent increase over sales of $9.35 million the same period last year.

Posted In: PSTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist